409 related articles for article (PubMed ID: 16516279)
1. Early cervical cancer and parametrial involvement: is it significant?
Steed H; Capstick V; Schepansky A; Honore L; Hiltz M; Faught W
Gynecol Oncol; 2006 Oct; 103(1):53-7. PubMed ID: 16516279
[TBL] [Abstract][Full Text] [Related]
2. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
Rutledge TL; Kamelle SA; Tillmanns TD; Gould NS; Wright JD; Cohn DE; Herzog TJ; Rader JS; Gold MA; Johnson GA; Walker JL; Mannel RS; McMeekin DS
Gynecol Oncol; 2004 Oct; 95(1):70-6. PubMed ID: 15385112
[TBL] [Abstract][Full Text] [Related]
3. How important is removal of the parametrium at surgery for carcinoma of the cervix?
Covens A; Rosen B; Murphy J; Laframboise S; DePetrillo AD; Lickrish G; Colgan T; Chapman W; Shaw P
Gynecol Oncol; 2002 Jan; 84(1):145-9. PubMed ID: 11748991
[TBL] [Abstract][Full Text] [Related]
4. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy.
Wright JD; Grigsby PW; Brooks R; Powell MA; Gibb RK; Gao F; Rader JS; Mutch DG
Cancer; 2007 Sep; 110(6):1281-6. PubMed ID: 17654664
[TBL] [Abstract][Full Text] [Related]
5. Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma.
Grisaru DA; Covens A; Franssen E; Chapman W; Shaw P; Colgan T; Murphy J; DePetrillo D; Lickrish G; Laframboise S; Rosen B
Cancer; 2003 Apr; 97(8):1904-8. PubMed ID: 12673716
[TBL] [Abstract][Full Text] [Related]
6. Early cervical carcinoma: the natural history of lymph node involvement redefined on the basis of thorough parametrectomy and giant section study.
Benedetti-Panici P; Maneschi F; D'Andrea G; Cutillo G; Rabitti C; Congiu M; Coronetta F; Capelli A
Cancer; 2000 May; 88(10):2267-74. PubMed ID: 10820348
[TBL] [Abstract][Full Text] [Related]
7. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy.
Ho CM; Chien TY; Huang SH; Wu CJ; Shih BY; Chang SC
Gynecol Oncol; 2004 May; 93(2):458-64. PubMed ID: 15099962
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with parametrial involvement in stage IB1 cervical cancer and identification of patients suitable for less radical surgery.
Kodama J; Kusumoto T; Nakamura K; Seki N; Hongo A; Hiramatsu Y
Gynecol Oncol; 2011 Sep; 122(3):491-4. PubMed ID: 21703671
[TBL] [Abstract][Full Text] [Related]
9. Extent of lymphovascular space invasion and risk of pelvic lymph node metastases in stage IB1 cervical cancer.
Chandacham A; Charoenkwan K; Siriaunkgul S; Srisomboon J; Suprasert P; Phongnarisorn C; Cheewakraingkrai C; Siriaree S; Tantipalakorn C; Kietpeerakool C
J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S31-6. PubMed ID: 17722314
[TBL] [Abstract][Full Text] [Related]
10. [Risk factors and prognosis of node-positive cervical carcinoma].
Feng SY; Zhang YN; Liu JG
Ai Zheng; 2005 Oct; 24(10):1261-6. PubMed ID: 16219145
[TBL] [Abstract][Full Text] [Related]
11. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
12. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma.
Diaz JP; Sonoda Y; Leitao MM; Zivanovic O; Brown CL; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2008 Nov; 111(2):255-60. PubMed ID: 18755500
[TBL] [Abstract][Full Text] [Related]
13. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?
Kamelle SA; Rutledge TL; Tillmanns TD; Gould NS; Cohn DE; Wright J; Herzog TJ; Rader JS; Gold MA; Johnson GA; Walker JL; Mannel RS; McMeekin DS
Gynecol Oncol; 2004 Aug; 94(2):249-55. PubMed ID: 15297159
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
[TBL] [Abstract][Full Text] [Related]
15. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.
dos Reis R; Frumovitz M; Milam MR; Capp E; Sun CC; Coleman RL; Ramirez PT
Gynecol Oncol; 2007 Dec; 107(3):458-63. PubMed ID: 17854872
[TBL] [Abstract][Full Text] [Related]
16. A comparison of laparascopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer.
Steed H; Rosen B; Murphy J; Laframboise S; De Petrillo D; Covens A
Gynecol Oncol; 2004 Jun; 93(3):588-93. PubMed ID: 15196849
[TBL] [Abstract][Full Text] [Related]
17. Changes in the demographics and perioperative care of stage IA(2)/IB(1) cervical cancer over the past 16 years.
Covens A; Rosen B; Murphy J; Laframboise S; DePetrillo AD; Lickrish G; Colgan T; Chapman W; Shaw P
Gynecol Oncol; 2001 May; 81(2):133-7. PubMed ID: 11330939
[TBL] [Abstract][Full Text] [Related]
18. Postoperative pelvic radiotherapy for cervical cancer patients with positive parametrial invasion.
Uno T; Ito H; Isobe K; Kaneyasu Y; Tanaka N; Mitsuhashi A; Suzuka K; Yamazawa K; Shigematsu N; Itami J
Gynecol Oncol; 2005 Feb; 96(2):335-40. PubMed ID: 15661218
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of patients after extraperitoneal lymph node dissection for cervical cancer.
Denschlag D; Gabriel B; Mueller-Lantzsch C; Tempfer C; Henne K; Gitsch G; Hasenburg A
Gynecol Oncol; 2005 Mar; 96(3):658-64. PubMed ID: 15721408
[TBL] [Abstract][Full Text] [Related]
20. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]